Sana Biotechnology's Q2 Earnings: $72.7M Cash Position, $177.2M Pro Forma Cash, and Q2 Cash Runway Until 2026.

Sana Biotechnology reported Q2 EPS of 16 cents, in line with consensus. The company's pro forma Q2 cash position is $177.2M, with a cash runway expected to last into the second half of 2026. Sana's President and CEO Steve Harr highlighted progress in the type 1 diabetes program, including FDA feedback on a HIP-edited GMP master cell bank, positive clinical results, and plans to file the IND for SC451 as early as next year.

Sana Biotechnology, Inc. (NASDAQ: SANA) reported its second-quarter 2025 earnings per share (EPS) of 16 cents, in line with analysts' consensus estimates. The company's pro forma Q2 cash position is $177.2 million, with a cash runway expected to extend into the second half of 2026. President and CEO Steve Harr highlighted significant progress in the company's type 1 diabetes program, including positive clinical results and plans to file the Investigational New Drug (IND) for SC451 as early as next year.

The company's cash position as of June 30, 2025, was $72.7 million, compared to $152.5 million at the end of 2024. This decrease was primarily due to cash used in operations, totaling $81.8 million [2]. Despite this, Sana Biotechnology has raised over $100 million in new capital since the end of the second quarter, strengthening its balance sheet and enabling further investment in its pipeline [1].

In the type 1 diabetes program, Sana reported positive 6-month clinical results for UP421, showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression can overcome immune recognition and persist with stable C-peptide levels. Additionally, the New England Journal of Medicine published positive 12-week clinical results for the same study [3]. The company expects to file the IND for SC451 as early as next year.

Sana Biotechnology is also advancing its pipeline across multiple indications and modalities. It is enrolling patients in the GLEAM and VIVID trials for SC291 and SC262, respectively, and expects to share data from these studies in 2025. The company is also pre-clinically developing SG299, a CD8-targeted fusosome for various B-cell cancers and autoimmune diseases, and expects to file an IND for SG299 as early as 2026 [3].

The company's financial results and business highlights were reported on August 11, 2025, and can be found on their investor relations page [3].

References:
[1] https://www.tipranks.com/news/the-fly/sana-biotechnology-reports-q2-eps-16c-consensus-21c-thefly
[2] https://seekingalpha.com/news/4483508-sana-biotechnology-non-gaap-eps-of--039
[3] https://ir.sana.com/news-releases/news-release-details/sana-biotechnology-reports-second-quarter-2025-financial-results